• 1
    Glatzle J, Sternini C, Robin C, et al. Expression of 5-HT3 receptors in the rat gastrointestinal tract. Gastroenterology 2002; 123(1): 21726.
  • 2
    Hillsley K, Grundy D. Sensitivity to 5-hydroxytryptamine in different afferent subpopulations within mesenteric nerves supplying the rat jejunum. J Physiol 1998; 509(3): 71727.
  • 3
    Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46(2): 157203.
  • 4
    Bearcroft CP, Andre EA, Farthing MJ. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther 1997; 11(6): 110914.
  • 5
    Li Y, Hao Y, Zhu J, Owyang C. Serotonin released from intestinal enterochromaffin cells mediates luminal non-cholecystokinin-stimulated pancreatic secretion in rats. Gastroenterology 2000; 118(6): 1197207.
  • 6
    Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990; 4(2): 13944.
  • 7
    Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7(2): 17580.
  • 8
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13(9): 114959.
  • 9
    Netzer P, Gaia C, Lourens ST, et al. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? Aliment Pharmacol Ther 2002; 16(1): 11927.
  • 10
    Kuo B, Camilleri M, Burton D, et al. Effects of 5-HT3 antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002; 16(2): 22533.
  • 11
    Wilmer A, Tack J, Coremans G, Janssens J, Peeters T, Vantrappen G. 5-Hydroxytryptamine-3 receptors are involved in the initiation of gastric phase-3 motor activity in humans. Gastroenterology 1993; 105(3): 77380.
  • 12
    Yano T, Yamazaki S, Tobe A. Effects of MKC-733, a new prokinetic agent, on the gastrointestinal tract. Digestion 1998; 59(Suppl. 3): 737(Abstract).
  • 13
    Yamazaki S, Yano T, Tobe A. Species difference in the intrinsic activity of MKC-733 for the 5-HT3 receptor. Jpn J Pharmacol 1996; 71(Suppl. 1): 62(Abstract).
  • 14
    Yano T, Kuwahara A, Yamakazi S. The effects of MKC-733, a new potent 5-HT3 receptor agonist, on ion transport of guinea pig distal colon. Jpn J Pharmacol 1996; 71(Suppl. 1): 109(Abstract).
  • 15
    Yamazaki S, Yano T, Ogawa S, Tobe A. Effects of MKC-733, a new prokinetic compound, on gastrointestinal motility in rats and dogs. Jpn J Pharmacol 1995; 67(Suppl. 1): 189(Abstract).
  • 16
    Bjornsson ES, Abrahamsson H. Contractile patterns in patients with severe chronic dyspepsia. Am J Gastroenterol 1999; 94(1): 5464.
  • 17
    Kong MF, Perkins AC, King P, Blackshaw PE, Macdonald IA. Reproducibility of gastric emptying of a pancake and milkshake meal in normal subjects. Nucl Med Commun 1998; 19(1): 7782.
  • 18
    Marciani L, Gowland PA, Spiller RC, et al. Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI. Am J Physiol Gastrointest Liver Physiol 2001; 280(6): G122733.
  • 19
    Marciani L, Young P, Wright J, et al. Echoplanar imaging in GI clinical practice: assessment of gastric emptying and antral motility in four patients. J Magn Reson Imaging 2000; 12(2): 3436.
  • 20
    Marciani L, Young P, Wright J, et al. Antral motility measurements by magnetic resonance imaging. Neurogastroenterol Motil 2001; 13(5): 5118.
  • 21
    Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16(7): 235264.
  • 22
    Schworer H, Ramadori G. Autoreceptors can modulate 5-hydroxytryptamine release from porcine and human small intestine in vitro. Naunyn Schmiedebergs Arch Pharmacol 1998; 357(5): 54852.
  • 23
    Hicks G, Hurle M, Savage T, Mazzia C, Clerc N, Humphrey P. Enterochromaffin cells of the human, rat and guinea-pig colon: lack of evidence for the presence of 5-HT3 receptors. Gastroenterology 2001; 120: A171(Abstract).
  • 24
    Nielsen OH, Hvid-Jacobsen K, Lund P, Langoholz E. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990; 46(2): 8996.
  • 25
    Zerbib F, Bruley DV, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8(4): 4037.
  • 26
    Reid K, Grundy D, Khan MI, Read NW. Gastric emptying and symptoms of vection induced nausea. Eur J Gastroenterol Hepatol 1995; 7(2): 1038.
  • 27
    Castro A, Mearin F, Larish J, Malagelada JR. Gastric fundus relaxation and emetic sequences induced by apomorphine and intragastric lipid infusion in healthy humans. Am J Gastroenterol 2000; 95(12): 340411.
    Direct Link:
  • 28
    Endo T, Minami M, Hirafuji M, et al. Neurochemistry and neuropharmacology of emesis — the role of serotonin. Toxicology 2000; 153(1–3): 189201.
  • 29
    Kerlin P. Postprandial antral hypomotility in patients with idiopathic nausea and vomiting. Gut 1989; 30(1): 549.
  • 30
    Talley NJ, Phillips SF, Haddad A, et al. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34(10): 15115.
  • 31
    Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994; 35(4): 496500.
  • 32
    Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996; 111(5): 128190.
  • 33
    Gunput MD. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 706.
  • 34
    Saxena PR, Villalon CM. Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol 1990; 15(Suppl. 7): S1734.
  • 35
    Nagakura Y, Kiso T, Miyata K, Ito H, Iwaoka K, Yamaguchi T. The effect of the selective 5-HT(3) receptor agonist on ferret gut motility. Life Sci 2002; 71(11): 13139.
  • 36
    Choi M-G, Kim B, Choo K, et al. Measurement of gastric accommodation and emptying of a solid meal by magnetic resonance imaging. Gastroenterology 2000; 118: A389(Abstract).
  • 37
    Boulby P, Gowland P, Adams V, Spiller RC. Use of echo planar imaging to demonstrate the effect of posture on the intragastric distribution and emptying of an oil/water meal. Neurogastroenterol Motil 1997; 9(1): 417.
  • 38
    Kuiken SD, Samsom M, Camilleri M, et al. Development of a test to measure gastric accommodation in humans. Am J Physiol 1999; 277(6 Part 1): G121721.
  • 39
    Fujita T, Kumagai Y, Yokota S, et al. The effects of a novel 5-HT3 agonist on symptoms of subjects with constipation and their intestinal motilities. Digestion 1998; 59(Suppl. 3): 744(Abstract).